Philip Burchard

Chief Executive Officer (Merz Group), Merz Pharma Merz

Search every verified Philip Burchard interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In interviews from 2019, Philip Burchard, then CEO of Merz Aesthetics, discussed the company's product portfolio and market strategy. He described Ultherapy as a non-invasive treatment using micro-focused ultrasound to create heat points under the skin that stimulate collagen production, leading to a gradual natural lifting effect. He also described Cellfina as a treatment for cellulite dimples that releases fibrous bands under the skin. Burchard stated that the company was working on combining its products, such as fillers, neuromodulators, and energy-based devices, in small quantities to achieve natural-looking results, and that it was conducting clinical trials to seek registration and approval for combination use. Burchard said that the aesthetic market was growing worldwide despite geopolitical challenges, and that Merz Aesthetics had established regional organizations in Asia, Latin America, and the Middle East to develop its presence. He stated that the company was developing new fillers internally and evaluating external innovations from startups and universities. He noted that Ultherapy was becoming increasingly popular and that the company was developing body indications, including for laxity under the arm and on the abdomen.